Leksum LLC, an early-stage life sciences company based in Boston, Massachusetts, announced on October 13, 2026, that it has signed an agreement with the Department of Anesthesia, Intensive Care Medicine and Pain Medicine at the Medical University of Vienna. The agreement, with Phoenestra GmbH as a co-signatory, covers preparatory work leading up to Phase I/II first-in-human clinical trials for LK-ICU, a biologic therapy designed to address acquired muscle myopathies.
LK-ICU consists of extracellular vesicles derived from bone marrow mesenchymal stromal cells. Preclinical studies indicate that the therapy almost completely preserves both diaphragm muscle fiber size and function, which are normally compromised by the use of mechanical ventilation. Prolonged weaning from mechanical ventilation, often caused by ICU-acquired weakness, is estimated to impact the quality of life of hundreds of thousands of patients each year in the U.S. and Europe. This condition can lead to extended hospital stays, increased healthcare costs, and long-term disability, making the development of effective therapies a significant public health priority.
The company plans to begin efforts under the agreement upon closing its Series A financing round. The planning phase is expected to last several months. Leksum intends to use European clinical data to support its U.S. regulatory path, potentially streamlining the approval process and bringing the therapy to market more quickly. This cross-continental strategy could serve as a model for other early-stage life sciences companies seeking to navigate complex regulatory landscapes.
Leksum's pipeline extends beyond LK-ICU to include skeletal muscle conditions such as sarcopenia, cancer cachexia, and muscle loss due to the use of weight-loss drugs like GLP-1s. The company's focus on acquired muscle myopathies addresses a broad range of unmet medical needs, from critical care to chronic conditions. For readers, this announcement signals potential future treatment options for muscle-wasting conditions that affect millions worldwide. For the healthcare industry, it highlights the growing interest in regenerative medicine approaches using extracellular vesicles, which may offer advantages over traditional cell therapies.
For full details, including downloadable images and bios, click here. The source of this announcement is Leksum.
